Tellgen released its performance for the first three quarters, with a net profit attributable to the parent company of 5.7749 million yuan, a decrease of 76.33%Zhitong·Oct 22, 2025 at 07:46 AM300642+0.42%
Tellgen: First repurchase of 0.13% of the company's sharesZhitong·Aug 28, 2025 at 06:46 AM300642+0.42%
Tellgen: Net profit of 2.7593 million yuan in the first half of 2025, a year-on-year decrease of 58.41%Zhitong·Aug 26, 2025 at 06:20 AM300642+0.42%
The gene sequencing sector surged in the short term, and Berry Genomics hit the limit upZhitong·Aug 6, 2025 at 08:39 PM301421-8.30%300642+0.42%
Tellgen's subsidiary Jiangxi Tellgen has obtained two medical device registration certificatesZhitong·Aug 6, 2025 at 05:26 AM300642+0.42%
Tellgen plans to acquire controlling stake in Kanglu Bio to pursue synergiesZhitong·Aug 4, 2025 at 09:11 AM300642+0.42%
Monkeypox concept stocks surged, KHB hit the limit upZhitong·Jul 27, 2025 at 08:33 PM002370-0.21%002022+0.60%
Tellgen: Obtained the change registration and registration certificate for medical devicesZhitong·Jul 24, 2025 at 07:38 AM300642+0.42%
Tellgen's subsidiary obtained 2 medical device registration certificatesZhitong·Jun 25, 2025 at 03:20 AM300642+0.42%
Tellgen's multiple medical device registration applications have been acceptedZhitong·Jun 16, 2025 at 03:06 AM300642+0.42%
Tellgen's shareholder Rongzhen Investment plans to reduce its holdings by no more than 0.71%Zhitong·Jun 2, 2025 at 03:55 AM300642+0.42%
Tellgen released its first-quarter performance, turning a loss into a profit of 471,700 yuanZhitong·Apr 27, 2025 at 05:18 AM300642+0.42%
Tellgen released its 2024 annual performance, with a net profit attributable to the parent company of 34.535 million yuan, a decrease of 61.37%Zhitong·Apr 18, 2025 at 10:17 AM300642+0.42%
Tellgen plans to spend between 20 million and 40 million yuan to implement a share repurchaseZhitong·Apr 8, 2025 at 05:12 AM300642+0.42%
